Specific inhibition of bile acid transport alters plasma lipids and GLP-1

BMC Cardiovascular Disorders

Volumn 15, Issue 1, 2015, Pages

  Rudling, Mats ^a   Camilleri, Michael ^b   Graffner, Hans ^c   Holst, Jens Juul ^d   Rikner, Leif ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAYO CLINIC   (United States)

^c Albireo   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dyslipidemia; Elobixibat; Glucagon like peptide 1 (GLP 1); Ileal bile acid (BA) transporter (IBAT) inhibitor

Indexed keywords

7ALPHA 4 HYDROXY 3 ONE; BILE ACID; BIOLOGICAL MARKER; ELOBIXIBAT; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 7 ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; CHOLEST 4 EN 3 ONE; DIPEPTIDE; LIPID; THIAZEPINE DERIVATIVE;

ABDOMINAL DISTENSION; ADULT; AREA UNDER THE CURVE; ARTICLE; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FEVER; HEADACHE; HUMAN; MYALGIA; PHARYNGITIS; POLYURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHINITIS; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; AGED; BIOSYNTHESIS; BLOOD; CHRONIC DISEASE; DYSLIPIDEMIAS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BILE ACIDS AND SALTS; CHOLESTENONES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHRONIC DISEASE; CONSTIPATION; DIPEPTIDES; DYSLIPIDEMIAS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIPIDS; MALE; MIDDLE AGED; THIAZEPINES; TRIGLYCERIDES; YOUNG ADULT;

EID: 84937706274     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-015-0070-9     Document Type: Article

References (33)

1. Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol. 2002;282:G443-449.
2. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest. 1971;50:1569-77.
3. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011;106:1803-12.
4. Simren M, Bajor A, Gillberg PG, Rudling M, Abrahamsson H. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study. Aliment Pharmacol Ther. 2011;34:41-50.
5. Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106:2154-64.
6. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis. 2011;29:37-44.
7. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167-77.
8. Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7{alpha}-hydroxylase activity by assay of the stable bile acid intermediate 7{alpha}-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res. 2003;44:859-66.
9. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329:386-90.
10. Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol. 2013;304:G371-380.
11. Carter D, Howlett HC, Wiernsperger NF, Bailey CJ. Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab. 2003;5:120-5.
12. Caspary WF, Creutzfeldt W. Inhibition of bile salt absorption by blood-sugar lowering biguanides. Diabetologia. 1975;11:113-7.
13. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med. 1998;15:651-6.
14. Gillberg PG, Dahlström M, Starke I, Ostlund-Lindquist A-M. The IBAT inhibition by A3309 - A potential mechanism for the treatment of constipation. Gastroenterology. 2010;138:S-224.
15. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-91.
16. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43:535-9.
17. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40:35-53.
18. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508.
19. Salmoirago-Blotcher E, Crawford S, Jackson E, Ockene J, Ockene I. Constipation and risk of cardiovascular disease among postmenopausal women. Am J Med. 2011;124:714-23.
20. Shakir YA, Samsioe G, Khatibi EA, Nyberg P, Lidfeldt J, Agardh CD, et al. Health hazards in middle-aged women with cardiovascular disease: a case-control study of swedish women. the women's health in the Lund area (WHILA) study. J Womens Health (Larchmt). 2007;16:406-14.
21. Angelin B, Eriksson M, Rudling M. Bile acids and lipoprotein metabolism: a renaissance for bile acids in the post-statin era? Curr Opin Lipid. 1999;10:269-74.
22. Abrahamsson H, Ostlund-Lindqvist AM, Nilsson R, Simren M, Gillberg PG. Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol. 2008;43:1483-8.
23. Hofmann AF, Loening-Baucke V, Lavine JE, Hagey LR, Steinbach JH, Packard CA, et al. Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr. 2008;47:598-606.
24. Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I, Bondar O, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2012;10:1009-15. e1003.
25. Charach G, Grosskopf I, Rabinovich A, Shochat M, Weintraub M, Rabinovich P. The association of bile acid excretion and atherosclerotic coronary artery disease. Therap Adv Gastroenterol. 2011;4:95-101.
26. Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep. 2012;2:430.
27. Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab. 2010;299:E10-13.
28. Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther. 2010;88:801-8.
29. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol. 2010;298:G419-424.
30. Chen L, Yao X, Young A, McNulty J, Anderson D, Liu Y, et al. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012;302:E68-76.
31. Brinton EA. Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation. Diabetes Obes Metab. 2008;10:1004-11.
32. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989-96.
33. Talley NJ, Jones M, Nuyts G, Dubois D. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol. 2003;98:1107-11.